FDA Drug-Component Receipt and Identity Testing: A Supplier-Document Workflow

A supplier’s certificate, SDS and specification are useful inputs to a pharmaceutical purchase. They do not, by themselves, release a chemical component for drug-product manufacture. In the United States, the receiving manufacturer’s quality system must control receipt, quarantine, sampling, testing, approval or rejection, and the records that connect those decisions to the actual lot.

This article outlines an evidence handoff for a pharmaceutical raw material receipt workflow. It is written for procurement, supplier quality, QC and warehouse teams buying chemicals or other components used in drug-product manufacture. It is not a claim that a particular product is suitable for a medicine or a substitute for the manufacturer’s GMP procedures, product filing commitments or quality-unit decisions.

Order the material in a way quality can recognise

Start with a controlled purchase description: material name and internal identifier, grade, approved manufacturer and manufacturing site where required, specification revision, pack, storage and transport conditions, intended use, documentation request and change-notification contact. Avoid purchasing under a loose trade name when the quality system expects a defined component code. The purchase record should make it possible to compare what was approved, what arrived and what QC later sampled.

FDA’s cGMP Q&A explains that manufacturers must establish procedures for testing and approval or rejection of components, drug-product containers and closures. It also points to 21 CFR 211.84 for component sampling and testing. Procurement should therefore avoid wording that promises release based only on a supplier CoA. A CoA may be part of the evidence reviewed under the site procedure, but it is not a blanket substitute for the receiving manufacturer’s controls.

For a pharmaceutical chemical supplier qualification documents request, ask for the current controlled specification, lot-specific CoA where available, SDS, origin or manufacturer information that can be shared, pack and closure description, retest or expiry information if assigned, and notice of relevant changes. Keep the supplier’s document revision and the buyer’s approved specification separate: the first describes the offer, while the second records the site’s agreed acceptance basis.

Protect the receipt-to-release status chain

A sound receiving workflow does not allow an accepted delivery appointment to become an implicit quality release. On arrival, warehouse personnel should follow the site procedure for identifying each container or lot, checking quantity and condition, recording receipt, assigning status and placing material under the required quarantine or segregation controls. The detailed mechanism varies by facility, but the principle is constant: an unapproved component must not be confused with an approved one.

The FDA cGMP regulation at 21 CFR 211.80 requires components to be withheld from use until they have been sampled, tested or examined, as appropriate, and released for use by the quality-control unit. For buyers, the operational consequence is simple: retain the PO, delivery record, label images or receiving checks permitted by policy, supplier lot identifier and document package so QC can link its sample and disposition to the correct material. Do not relabel a supplier lot into an internal status that suggests approval before the authorised quality decision.

A drug component quarantine and release screen should flag damaged seals, wrong grade, changed manufacturer, documentation mismatch, unexpected transport condition, out-of-date revision, split lot, missing lot number or a change in pack configuration. The screen does not decide scientific acceptability. It routes the exception to quality, warehouse and supplier contacts before use. Keep the release status in the controlled inventory system, not in a buyer’s email thread.

Understand what identity testing is designed to establish

FDA’s Q&A on control of components states that representative samples of each shipment of each lot of active and inactive components must be tested to confirm identity before release for use in drug-product manufacturing. It also notes that more than one test can be necessary to establish identity, depending on the component. That is why a supplier’s assay result or a familiar container appearance cannot be treated as an identity conclusion by procurement.

The Q&A further explains that 21 CFR 211.84(b) sets principles for designing a sampling program and does not prescribe a single number of containers. The receiving site’s written procedure should therefore establish the plan, including how it handles lot definition, container selection, sampling controls, test method, acceptance criteria and any scientifically justified reduced testing. Procurement’s useful contribution is to preserve traceability and alert QC early when a shipment does not match the approved supplier, site, lot pattern or package.

For an FDA component identity testing requirements handoff, send QC the supplier name, manufacturing or distribution site as relevant, component code, lot number, container count, quantity, condition, CoA and specification revisions, and any approved change reference. Give the team time to test, review and disposition before the material is required in production. A rushed purchase order should not force an informal shortcut around sampling or release controls.

Evaluate supplier data without confusing it with site responsibility

Supplier data matters because it enables the receiving manufacturer to assess the proposal, plan incoming work and investigate deviations. Yet FDA’s cGMP Q&A makes clear that the manufacturer maintains the quality system and quality unit responsibilities. A supplier should provide truthful, current product data; the drug manufacturer determines what evidence and controls are required for its materials and process.

Where a component changes, build a before-and-after comparison: approved and proposed manufacturer or site, grade, compendial claim if any, specification, test method, impurity or water limits where relevant, container/closure, origin information, documentation revision and effective date. Route it through the site’s change-control and supplier-quality process. Do not claim that the change is GMP-neutral merely because the assay remains similar. Product-specific process knowledge, filings and quality agreements can create additional obligations.

Link the record to analytical testing, controlled documentation and lot traceability. Those site pages describe the kind of technical discussion a buyer can start; they do not represent a release decision or a pharmaceutical certification.

Use a practical request and escalation list

A concise 21 CFR 211.84 supplier documentation checklist includes: approved material identifier; purchase specification revision; proposed supplier and manufacturing site; lot and container identifiers; CoA and SDS versions; package and storage details; delivery condition; change declaration; receiving exception record; QC sample reference; and final authorised disposition. It gives each group a defined handoff without duplicating the quality-management system.

When asking a supplier for a pharmaceutical solvent or reagent, provide the intended non-confidential application, grade, required attributes, pack, destination, expected volume, required documents and qualification timing through the pharmaceutical component document-review route. The resulting discussion can identify available product evidence and the appropriate next step. It cannot pre-approve material for a drug product or replace the receiving manufacturer’s cGMP process.